Puma Biotechnology (PBYI) Operating Leases (2019 - 2026)
Puma Biotechnology's (PBYI) quarterly Operating Leases came in at $4.5 million in Q1 2026, down 20.77% YoY from $5.7 million in Q1 2025, and down 3.46% on a QoQ basis from $4.7 million in Q4 2025.
Puma Biotechnology (PBYI) Operating Leases (2019 - 2026) Analysis & Trends
Puma Biotechnology (PBYI) has 8 years of Operating Leases data on file, last reported at $4.5 million in Q1 2026.
- Quarterly Operating Leases fell 20.77% year-over-year to $4.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.5 million (down 20.77% YoY) and the FY2025 annual result came in at $4.7 million, up 215.19% from the prior year.
- Operating Leases retreated to $4.5 million in Q1 2026, from $4.7 million in the prior quarter.
- In the past five years, Operating Leases ranged from a high of $15.0 million in Q1 2022 to a low of $1.5 million in Q4 2024.
- A 5-year average of $8.9 million and a median of $8.3 million in 2024 frame the typical range for Operating Leases.
- Annual changes were most pronounced in 2024 — Operating Leases tumbled 78.76% — and 2025, when it soared 215.19%.
- Tracing PBYI's Operating Leases over 5 years: stood at $11.8 million in 2022, then tumbled by 40.56% to $7.0 million in 2023, then plunged by 78.76% to $1.5 million in 2024, then soared by 215.19% to $4.7 million in 2025, then declined by 3.46% to $4.5 million in 2026.
- The last three Operating Leases figures came in at $4.5 million (Q1 2026), $4.7 million (Q4 2025), and $4.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Puma Biotechnology | 451.24 Mn | 357.33 Mn | 44.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.82 Mn |
| Mar 31, 2026 | 4.55 Mn |
| Dec 31, 2025 | 4.71 Mn |
| Sep 30, 2025 | 4.87 Mn |
| Jun 30, 2025 | 4.36 Mn |
| Mar 31, 2025 | 5.74 Mn |
| Dec 31, 2024 | 1.49 Mn |
| Sep 30, 2024 | 8.30 Mn |
| Jun 30, 2024 | 9.52 Mn |
| Mar 31, 2024 | 5.74 Mn |
| Dec 31, 2023 | 7.03 Mn |
| Sep 30, 2023 | 12.92 Mn |
| Jun 30, 2023 | 13.98 Mn |
| Mar 31, 2023 | 15.01 Mn |
| Dec 31, 2022 | 11.83 Mn |
| Sep 30, 2022 | 12.92 Mn |
| Jun 30, 2022 | 13.98 Mn |
| Mar 31, 2022 | 15.01 Mn |
| Dec 31, 2021 | 15.98 Mn |
| Sep 30, 2021 | 20.37 Mn |